Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, 505 Parnassus Ave, M1093A, San Francisco, CA 94143-2204, USA.
Division of Cardiothoracic Surgery, Univeristy of California, San Francisco, 500 Parnassus Ave, MU 405W Suite 305, San Francisco, CA 94143, USA.
Thorac Surg Clin. 2022 May;32(2):231-242. doi: 10.1016/j.thorsurg.2021.11.004.
Chronic lung allograft dysfunction (CLAD) is a syndrome of progressive lung function decline, subcategorized into obstructive, restrictive, and mixed phenotypes. The trajectory of CLAD is variable depending on the phenotype, with restrictive and mixed phenotypes having more rapid progression and lower survival. The mechanisms driving CLAD development remain unclear, though allograft injury during primary graft dysfunction, acute cellular rejection, antibody-mediated rejection, and infections trigger immune responses with long-lasting effects that can lead to CLAD months or years later. Currently, retransplantation is the only effective treatment.
慢性肺移植功能障碍(CLAD)是一种进行性肺功能下降的综合征,可分为阻塞性、限制性和混合性表型。CLAD 的发展轨迹因表型而异,限制性和混合性表型进展更快,生存率更低。尽管原发性移植物功能障碍、急性细胞排斥反应、抗体介导的排斥反应和感染导致的移植物损伤会触发具有持久影响的免疫反应,从而导致 CLAD 在数月甚至数年后发生,但导致 CLAD 发展的确切机制仍不清楚。目前,再次移植是唯一有效的治疗方法。